ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL

被引：0
|
作者：
McEwan, P. [1 ]
Evans, L. M. [2 ]
Bergenheim, K. [3 ]
机构：
[1] CRC, Cardiff, S Glam, Wales
[2] Univ Wales Hosp, Cardiff, Vale Glamorga, Wales
[3] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72108-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A293 / A293
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF XIGDUO (EXTENDED-RELEASE DAPAGLIFLOZIN-METFORMIN TABLETS) FOR MANAGING TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS
    Bao, H.
    Liu, Q.
    Peng, X.
    Xuan, J.
    VALUE IN HEALTH, 2024, 27 (06) : S122 - S122
  • [32] COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA
    Daacke, I
    Kandaswamy, P.
    Tebboth, A.
    Kansal, A.
    Reifsnider, O.
    VALUE IN HEALTH, 2016, 19 (07) : A673 - A673
  • [33] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [34] COST-EFFECTIVENESS ANALYSIS FOR SOLIQUA IN THE TREATMENT OF T2DM IN TURKIYE
    Atikeler, K.
    Kurnaz, M.
    Ileri, S.
    Cansever, M.
    Kahveci, S.
    Kader, B.
    Duran, C.
    Akbay, E. E.
    Karacar, G.
    Ozturk, F.
    Okcun, S.
    Kockaya, G.
    VALUE IN HEALTH, 2023, 26 (12) : S112 - S112
  • [35] Health-related Quality-of-Life (HRQoL) Implications of Cardiovascular Events in Type 2 Diabetes Mellitus (T2DM)
    Briggs, Andrew
    Bhatt, Deepak
    Scirica, Benjamin M.
    Mosenzon, Ofri
    Johnston, Karissa
    Szabo, Shelagh
    Bergenheim, Klas
    Mukherjee, Jayanti
    Hirshberg, Boaz
    Raz, Itamar
    DIABETES, 2015, 64 : A659 - A659
  • [36] Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk
    Sonesson, C.
    Frederich, R.
    Johansson, P. A.
    Gause-Nilsson, I.
    Langkilde, A. M.
    List, J. F.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1072 - 1072
  • [37] THE PREVALENCE OF MICROALBUMINURIA IN CHILDREN WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Yafi, Michael
    ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 : A250 - A250
  • [38] Regional effects of type 2 diabetes mellitus (T2DM) on neurodegeneration
    Moran, C.
    Phan, T. G.
    Beare, R. J.
    Chen, J.
    Blizzard, L.
    Venn, A.
    Greenaway, T.
    Munch, G.
    Forbes, J.
    Pearson, S.
    Srikanth, V
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 : 20 - 20
  • [39] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    DIABETIC MEDICINE, 2008, 25
  • [40] Cost of Major Adverse Cardiac Events (MACE) among Type 2 Diabetes Mellitus (T2DM) Patients with Obesity, Renal Impairment, or Varying Cardiovascular Risk
    Johnston, Stephen
    Shah, Manan
    Sheehan, Jack
    Cappell, Katherine
    Princic, Nicole
    Smith, David M.
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A619 - A619
12345